BM is preferred over PBSCs in transplantation from an HLA-matched related female donor to a male recipient.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
11 06 2019
11 06 2019
Historique:
received:
26
02
2019
accepted:
14
04
2019
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
3
7
2020
Statut:
ppublish
Résumé
The use of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells (PBSCs) and sex-mismatched hematopoietic cell transplantation (HCT), especially with female donors and male recipients (FtoM), is known to be associated with an increased risk of chronic graft-versus-host disease (GVHD) compared with transplantation with bone marrow (BM). This raises the question of whether the use of PBSCs in FtoM HCT might affect allogeneic responses, resulting in fatal complications. Using a Japanese transplantation registry database, we analyzed 1132 patients (FtoM, n = 315; MtoF, n = 260; sex-matched, n = 557) with standard-risk diseases who underwent HCT with an HLA-matched related donor without in vivo T-cell depletion between 2013 and 2016. The impact of PBSC vs BM on transplantation outcomes was separately assessed in FtoM, MtoF, and sex-matched HCT. Overall survival (OS) and nonrelapse mortality (NRM) at 2 years post-HCT were significantly worse in patients with PBSCs vs those with BM in FtoM HCT (2-year OS, 76% vs 62%;
Identifiants
pubmed: 31182560
pii: bloodadvances.2019000077
doi: 10.1182/bloodadvances.2019000077
pmc: PMC6560341
doi:
Substances chimiques
HLA Antigens
0
Types de publication
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1750-1760Informations de copyright
© 2019 by The American Society of Hematology.
Références
Haematologica. 2016 Jan;101(1):e30-3
pubmed: 26494841
Blood. 2015 May 14;125(20):3193-201
pubmed: 25766725
Int J Hematol. 2007 Oct;86(3):269-74
pubmed: 17988995
Ann Hematol. 2012 Mar;91(3):427-37
pubmed: 21789620
Biol Blood Marrow Transplant. 2009 Nov;15(11):1415-21
pubmed: 19822301
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2001 Oct 1;98(7):2043-51
pubmed: 11567988
Blood. 2005 Apr 1;105(7):2973-8
pubmed: 15613541
Bone Marrow Transplant. 2014 Feb;49(2):228-35
pubmed: 24076549
Haematologica. 2019 Jul;104(7):e314-e317
pubmed: 30655371
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Blood. 2011 Mar 17;117(11):3214-9
pubmed: 21263156
Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9
pubmed: 19203728
Br J Haematol. 2013 Feb;160(3):288-302
pubmed: 23205489
Bone Marrow Transplant. 2005 Mar;35(6):609-17
pubmed: 15696179
Curr Opin Oncol. 2012 Mar;24(2):191-6
pubmed: 22185938
Blood. 2012 Jan 5;119(1):296-307
pubmed: 22010102
Blood. 2004 Jan 1;103(1):347-52
pubmed: 12969970
J Clin Oncol. 2005 Aug 1;23(22):5074-87
pubmed: 16051954
Lancet. 2009 May 2;373(9674):1550-61
pubmed: 19282026
Blood. 2012 Oct 4;120(14):2796-806
pubmed: 22859606
Am J Med. 1980 Aug;69(2):204-17
pubmed: 6996481
Int J Hematol. 2015 May;101(5):438-51
pubmed: 25812839
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Biol Blood Marrow Transplant. 2017 Aug;23(8):1241-1249
pubmed: 28495640
Int J Hematol. 2016 Jan;103(1):11-9
pubmed: 26588927
Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74
pubmed: 25445023
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3005-10
pubmed: 23382226
Transpl Int. 2011 May;24(5):469-76
pubmed: 21294789
Int J Hematol. 2016 Jan;103(1):3-10
pubmed: 26547570
Blood. 2012 Mar 15;119(11):2675-8
pubmed: 22308289
Blood. 2002 Sep 1;100(5):1525-31
pubmed: 12176866
Haematologica. 2015 Nov;100(11):1477-85
pubmed: 26250581
Lancet. 2000 Apr 8;355(9211):1231-7
pubmed: 10770306
Immunol Res. 2014 May;58(2-3):249-58
pubmed: 24781195
Crit Rev Oncol Hematol. 2015 May;94(2):179-88
pubmed: 25604498
Blood. 2014 Jun 5;123(23):3664-71
pubmed: 24744269